10月7日 - ** 药物开发商泰罗米尔制药公司TELO.O股价盘前上涨24.7%至1.77美元
** 该公司周一晚些时候表示，其实验性药物Telomir-1在针对侵袭性前列腺癌的临床前研究中显示出前景 (link)，有可能帮助人体对抗肿瘤扩散和抗药性。
** 这种疗法能够恢复两个关键抑癌基因的活性，而癌细胞中的这两个基因往往由于 DNA 甲基化异常而被关闭。
** 泰洛米尔公司补充说，这种药物在与化疗同时使用时效果更好，在逆转基因沉默方面显示出更强的作用
** 截至上一交易日收盘，股价累计下跌 65
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.